Drug Trial Radar · NCT04207463
A Study of Anlotinib and AK105 Injection in Subjects With Gastrointestinal Tumors, Urinary System Tumors, Neuroendocrine Tumors
Last checked: Nov 19, 2026Latest source record: Jun 17, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
150
Planned (sponsor's estimate)
Start
Jun 3, 2020
Primary completion
Dec 31, 2020
Study completion May 30, 2021
Sponsor
- Lead sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Dec 20, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
AK105 is a humanized monoclonal antibody that specially binds to PD-1. Anlotinib is a small molecule tyrosine kinase inhibitor. Based on the mechanism study, tumor vascular abnormalities promote tissue hypoxia and increase lactic acid, thereby activating immunosuppression and inhibiting T cell function. Anti-angiogenic drugs enhance the infiltration of effector immune cells by inducing normalization of blood vessels and reducing immunosuppression.
Conditions
- Gastrointestinal Tumors, Urinary System Tumors, Neuroendocrine Tumors
Interventions
AK105Drug
AK105 is a humanized monoclonal antibody that specifically binds to PD-1. AK105 has a typical antibody structure and is composed of two lgG1 subtype heavy chains and two kappa subtypes light chains covalently linked by disulfide bonds.
AnlotinibDrug
a multi-target receptor tyrosine kinase inhibitor
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall response rate (ORR)Time frame: up to 96 weeks
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Beijing, Beijing Municipality, China · Recruiting
Beijing Hospital
Beijing, Beijing Municipality, China · Not yet recruiting
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China · Not yet recruiting
Jiangsu Cancer Hospital
Nanjing, Jiangsu, China · Recruiting
Harbin Medical University Cancer Hospital
Harbin, Jilin, China · Not yet recruiting
Jinan Central Hospital
Jinan, Shandong, China · Recruiting
Shanxi Provincial Cancer Hospital
Xi’an, Shanxi, China · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.